Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

Drugs

Volumn 59, Issue 6, 2000, Pages 1233-1250

  Kaakkola, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE; TOLCAPONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEPATITIS; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PARKINSON DISEASE; REVIEW; RHABDOMYOLYSIS; SLEEP DISORDER;

ANIMALIA;

EID: 0034095886     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059060-00004     Document Type: Review

References (109)

1. 1. Axelrod J. O-methylation of epinephrine and other catechols in vitro and in vivo. Science 1957; 126: 400-1
2. 2. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206
3. 3. Ericsson AD. Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 1971; 14: 193-7
4. 4. Reches A, Fahn S. Catechol-O-methyltransferase and Parkinson's disease. Adv Neurol 1984; 40: 171-9
5. 5. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990; 66: 317-23
6. 6. Männistö PT, Ulmanen I, Taskinen J, et al. Catechol-O-methyltransferase (COMT) and COMT inhibitors, In: Sandler M, Smith J, editors. Design of enzyme inhibitors as drugs. Oxford: Oxford University Press, 1993; 623-46
7. 7. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994; 25: 813-24
8. 8. Pentikäinen PJ, Vuorela A, Järvinen M, et al. Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor. Eur J Clin Pharmacol 1989; 36 Suppl.: A110
9. 9. Kaakkola S, Gordin A, Järvinen M, et al. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 1990; 13: 436-47
10. 10. Bieck PR, Nilsson E, Antonin KH. Effect of the new selective COMT inhibitor CGP28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J Neural Transm Suppl 1990; 32: 387-91
11. 11. Bieck PR, Antonin KH, Farger G, et al. Clinical pharmacology of the new COMT inhibitor CGP 28,014. Neurochem Res 1993; 18: 1163-7
12. 12. Feuerstein C, Tanche M, Serre F, et al. Does O-methyl-dopa play a role in levodopa-induced dyskinesias? Acta Neurol Scand 1977; 56: 79-82
13. 13. Rivera-Calimlim L, Tandon D, Anderson F, et al. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 1977; 34: 228-32
14. 14. Tohgi H, Abe T, Kikuchi T, et al. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci Lett 1991; 132: 19-22
15. 15. Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975; 17: 131-6
16. 16. McKenzie GM, White HL. Evidence for the methylation of apomorphine by catechol-O-methyl-transferase in vivo and in vitro. Biochem Pharmacol 1973; 22: 2329-36
17. 17. Symes AL, Lal S, Sourkes TL. Effect of catechol-O-methyl-transferase inhibitors on brain apomorphine concentrations and stereotyped behaviour in the rat. J Pharm Pharmacol 1975; 27: 947-9
18. 18. Coudore F, Durif F, Duroux E, et al. Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport 1997; 8: 877-80
19. 19. Kohli JD, Horn PT, Glock D, et al. Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur J Pharmacol 1993; 235: 31-5
20. 20. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994; 46: 151-7
21. 21. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995; 57: 508-17
22. 22. Heikkinen H, Pentikäinen PJ, Saraheimo M, et al. Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: a study using stable isotope technique. New Trends Clin Neuropharm 1994; 8: 301
23. 23. Jorga KM, Fotteler B, Heizmann P, et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 1998; 54: 443-7
24. 24. Wikberg T, Vuorela A, Ottoila P, et al. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993; 21 : 81-92
25. 25. F. Hoffman-La Roche Ltd. Product monograph Tasmar. Basel: F. Hoffman-La Roche Ltd, 1997: 1-60
26. 26. Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1995; 17: S26-S37
27. 27. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50: 47-55
28. 28. Jorga K, Fotteler B, Wiegand U. Tolcapone does not change the pharmacokinetics and pharmacodynamics of the CYP2C9 substrate tolbutamide. Mov Disord 1997; 12 Suppl. 1: 100
29. 29. Gordin A, Huupponen R, Rouru J, et al. Pharmacokinetics of entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of entacapone and effect on levodopa metabolism. Eur J Neurol 1998; 5 Suppl. 3: S165-S6
30. 30. Jorga KM, Sedek G, Fotteler B, et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997; 62: 300-10
31. 31. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995; 40: 253-62
32. 32. Jorga K, Fotteler B, van Brummelen P. Why should tolcapone be given at a lower dose to patients with liver cirrhosis? Clin Pharmacol Ther 1997; 61: 183
33. 33. Gordin A, Pentikäinen PP, Mäkimartti M, et al. Pharmacokinetics of the COMT inhibitor entacapone in liver failure and the effect of entacapone on liver function. Neurology 1998; 50 Suppl. 4: A387
34. 34. Comtess Summary of Product Characteristics. Espoo, Finland: Orion Corp., 1998
35. 35. Schultz E, Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 1989; 38: 3953-6
36. 36. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-10
37. 37. Borges N, Vieira-Coelho MA, Parada A, et al. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 1997; 282: 812-7
38. 38. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145-56
39. 39. Sêdek G, Jorga K, Schmitt M, et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997; 20: 531-41
40. 40. Jorga K, Fotteler B, Schmitt M, et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 1997; 38: 59-67
41. 41. Myllylä VV, Sotaniemi KA, Mäkimartti M, et al. Effect of entacapone as an adjunct to Sinemet and Madopar on the pharmacokinetics of levodopa in parkinsonian patients. Mov Disord 1997; 12 Suppl. 1: 103
42. 42. Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998; 245: 223-30
43. 43. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995; 18: 46-57
44. 44. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996; 19: 283-96
45. 45. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996; 19: 222-33
46. 46. Myllylä VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993; 45: 419-23
47. 47. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913-9
48. 48. Tohgi H, Abe T, Yamazaki K, et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192: 165-8
49. 49. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993; 43: 2685-8
50. 50. Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. Clin Neuropharmacol 1995; 18: 258-65
51. 51. Yamamoto M, Yokochi M, Kuno S, et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm 1997; 104: 229-36
52. 52. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995; 2: 341-7
53. 53. Kuruma I, Bartholini G, Tissot R, et al. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971; 12: 678-82
54. 54. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36-40
55. 55. Sundberg S, Scheinin M, Illi A, et al. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993; 36: 451-6
56. 56. Illi A, Sundberg S, Koulu M, et al. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994; 32: 582-8
57. 57. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993; 60: 641-7
58. 58. Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease. Mov Disord 1997; 12: 497-505
59. 59. Oechsner M, Stürenburg HJ, Buhmann C, et al. Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition. Eur J Neurol 1998; 5 Suppl. 3: S169
60. 60. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995; 18: 333-7
61. 61. Tasmar Summary of Product Characteristics. Basle, Switzerland: F. Hoffman-La Roche Ltd., 1998
62. 62. Firnau G, Sood S, Chirakal R, et al. Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med 1988; 29: 363-9
63. 63. Firnau G, Sood S, Chirakal R, et al. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 1987; 48: 1077-82
64. 64. Guttman M, Leger G, Cedarbaum JM. OR-611 inhibits 3-Omethyldopa formation in primates. Neurology 1991; 41: 213
65. 65. Günther I, Psylla M, Reddy GN, et al. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. Nucl Med Biol 1995; 22: 921-7
66. 66. Doudet DJ, Chan GL, Holden JE, et al. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 1997; 36: 363-71
67. 67. Psylla M, Günther I, Antonini A, et al. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res 1997; 767: 45-54
68. 68. Holden JE, Doudet D, Endres CJ, et al. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J Nucl Med 1997; 38: 1568-74
69. 69. Laihinen A, Rinne JO, Rinne UK, et al. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 1992; 42: 199-203
70. 70. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994; 44: 1292-7
71. 71. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cerebral Blood Flow Metab 1996; 16: 854-63
72. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dem Sect 1995; 10: 91-106
73. 73. Ruottinen HM, Rinne JO, Oikonen VJ, et al. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 1997; 27: 336-46
74. 74. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 186-9
75. 75. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995; 10: 349-51
76. 76. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55
77. 77. Rinne UK, Larsen JP, Siden Å, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-14
78. 78. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998; 55: 1089-95
79. 79. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81-7
80. 80. Myllylä VV, Jackson M, Larsen JP, et al. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off' phenomenon: a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 1997; 4: 333-41
81. 81. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421-8
82. 82. Rajput AH, Martin W, Sainthilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-71
83. 83. Limousin P, Pollak P, Gervason-Tournier CL, et al. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 1993; 341: 1605
84. 84. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase (COMT) inhibitor Ro 40-7592 prolongs duration of action of levodopa/carbidopa in parkinsonian patients. Neurology 1993; 43 Suppl. 2: A332
85. 85. Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997; 12: 928-34
86. 86. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997; 49: 665-71
87. 87. Agid Y, Destee A, Durif F, et al. Tolcapone, bromocriptine, and Parkinson's disease. Lancet 1997; 350: 712-3
88. 88. Harper J, Vieira B. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet 1998; 352: 578
89. 89. Henry C, Wilson JA. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet 1998; 351: 1965-6
90. 90. Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Mov Disord 1998; 13: 643-7
91. 91. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998; 352: 958
92. 92. EMEA. Recommendation for the suspension of the marketing authorisation for Tasmar (tolcapone) [press release]. Vol. CPMP/2457/98. London, 1998
93. 93. Tasmar Product Label. Nutley (NJ): Roche Laboratories Inc., 1998
94. 94. Jorga KM, Larsen JP, Beiske A, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999; 6: 211-19
95. 95. Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm Gen Sect 1991; 85: 11-7
96. 96. Illi A, Sundberg S, Ojala-Karlsson P, et al. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 1995; 58: 221-7
97. 97. Lyytinen J, Kaakkola S, Teräväinen H, et al. Comparison between the effects of L-dopa + entacapone and L-dopa + placebo on exercise capacity, haemodynamics and autonomic function in patients with Parkinson's disease. Mov Disord 1997; 12 Suppl. 1: 103
98. 98. Sedek G, Jorga K, Yoo K, et al. Lack of interaction between ephedrine and combination of tolcapone and sinemet. Neurology 1996; 46 Suppl. 2: 374
99. 99. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996; 59: 450-7
100. 100. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996; 51: 273-6
101. 101. Jorga K, Fotteler B, Sedek G, et al. Effect of the COMT inhibitor tolcapone on the hemodynamics effects and tolerability of the combination treatment with levodopa/carbidopa and desipramine in healthy volunteers. Neurology 1997; 48 Suppl.: A185
102. 102. Campbell NRC, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991; 31: 251-5
103. 103. Orama M, Tilus P, Taskinen J, et al. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J Pharm Sci 1997; 86: 827-31
104. 104. Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998; 351: 1221-2
105. 105. Khromova I, Voronina T, Kraineva VA, et al. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav Brain Res 1997; 86: 49-57
106. 106. Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 1994; 5: 344-50
107. 107. Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson's Disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methione-sparing effect. Clin Neuropharmacol 1994; 17 Suppl. 3: S26-37
108. 108. Yassin MS, Cheng H, Ekblom J, et al. Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosyl-methionine and S-adenosylhomocysteine in the rat brain. Neurochem Int 1998; 32: 53-9
109. 109. Gasparini M, Fabrizio E, Bonifati V, et al. Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm 1997; 104: 887-94